Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin versus medium-chain triglycerides in pediatric LC-FAOD
2022-001539-10Phase 3Active
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cenegermin and Miglyol Oil 812 in long-chain fatty acid oxidation disorder (LC-FAOD) (2 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Annualized event rate of major clinical events. Started Oct 2022; status: active.
02
Drugs
cenegerminMiglyol Oil 812
03
Conditions
long-chain fatty acid oxidation disorder (LC-FAOD)
Beyond the preview
Go deeper on 2022-001539-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001539-10.